About Omeros PipelineInvestorsNews

Press Releases

Date Title  
02/14/19 Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has
02/12/19 Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors.
01/17/19 Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent
01/14/19 Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 .